Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedDec 29, 2025
DataAggregated Company Financials
Companies152
  • 7D0.5%
  • 3M-2.7%
  • 1Y-7.2%
  • YTD-8.8%

The Healthcare is pretty flat in the last 7 days, but Vitrolife has stood out, gaining 3.9%. Unfortunately though, the industry is down 7.2% over the past 12 months. As for the next few years, earnings are expected to grow by 30% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 30 Dec 2025SEK 583.9bSEK 230.4bSEK 3.6b43.6x160.2x2.5x
Thu, 27 Nov 2025SEK 601.8bSEK 230.8bSEK 3.2b42.5x186.2x2.6x
Sat, 25 Oct 2025SEK 614.4bSEK 228.3bSEK 3.1b48.6x200.7x2.7x
Mon, 22 Sep 2025SEK 618.8bSEK 227.4bSEK 6.6b46x93.8x2.7x
Wed, 20 Aug 2025SEK 617.8bSEK 227.1bSEK 6.5b44.4x95x2.7x
Fri, 18 Jul 2025SEK 634.7bSEK 227.8bSEK 6.6b44.9x96.8x2.8x
Sun, 15 Jun 2025SEK 603.9bSEK 226.4bSEK 5.8b40.1x103.6x2.7x
Tue, 13 May 2025SEK 605.2bSEK 224.0bSEK 5.2b35.4x115.7x2.7x
Thu, 10 Apr 2025SEK 507.2bSEK 221.4bSEK 5.4b30.1x93.3x2.3x
Sat, 08 Mar 2025SEK 557.2bSEK 205.9bSEK 4.7b36x118.3x2.7x
Mon, 03 Feb 2025SEK 602.2bSEK 204.1bSEK 1.5b43.6x394.3x2.9x
Wed, 01 Jan 2025SEK 581.6bSEK 202.6b-SEK 2,502,931,625.7039x-232.4x2.9x
Fri, 29 Nov 2024SEK 516.4bSEK 199.4b-SEK 2,982,923,794.2636.4x-173.1x2.6x
Sun, 27 Oct 2024SEK 597.4bSEK 201.8b-SEK 2,327,827,882.9739.7x-256.6x3x
Tue, 24 Sep 2024SEK 615.2bSEK 200.1b-SEK 2,816,505,402.9141.3x-218.4x3.1x
Thu, 22 Aug 2024SEK 593.3bSEK 199.9b-SEK 1,827,902,985.6441.5x-324.6x3x
Sat, 20 Jul 2024SEK 590.0bSEK 198.0b-SEK 2,773,387,911.6143.5x-212.7x3x
Mon, 17 Jun 2024SEK 555.8bSEK 195.5b-SEK 3,170,352,917.2135.3x-175.3x2.8x
Wed, 15 May 2024SEK 556.2bSEK 196.7b-SEK 2,686,914,216.2136.1x-207x2.8x
Fri, 12 Apr 2024SEK 524.1bSEK 192.7b-SEK 3,173,168,722.5145.1x-165.2x2.7x
Sun, 10 Mar 2024SEK 525.5bSEK 192.1b-SEK 3,679,319,655.6243.5x-142.8x2.7x
Tue, 06 Feb 2024SEK 516.0bSEK 188.9b-SEK 4,141,640,228.2549.4x-124.6x2.7x
Thu, 04 Jan 2024SEK 537.0bSEK 191.4b-SEK 966,531,651.0046.9x-555.6x2.8x
Sat, 02 Dec 2023SEK 502.0bSEK 190.5b-SEK 1,082,699,817.0052.1x-463.6x2.6x
Mon, 30 Oct 2023SEK 430.6bSEK 188.4b-SEK 1,511,030,224.0032x-284.9x2.3x
Wed, 27 Sep 2023SEK 447.2bSEK 185.2b-SEK 2,036,963,813.0035.5x-219.5x2.4x
Fri, 25 Aug 2023SEK 458.4bSEK 185.1b-SEK 1,828,666,862.0038.7x-250.7x2.5x
Sun, 23 Jul 2023SEK 478.1bSEK 182.8b-SEK 1,004,494,296.0041.5x-476x2.6x
Tue, 20 Jun 2023SEK 496.7bSEK 179.2b-SEK 777,627,020.0045.7x-638.7x2.8x
Thu, 18 May 2023SEK 519.0bSEK 177.1b-SEK 863,515,969.0042.5x-601x2.9x
Sat, 15 Apr 2023SEK 513.9bSEK 172.6b-SEK 1,425,668,652.0035.8x-360.4x3x
Mon, 13 Mar 2023SEK 484.5bSEK 172.7b-SEK 1,409,179,377.0036.8x-343.8x2.8x
Wed, 08 Feb 2023SEK 525.1bSEK 167.5bSEK 279.4m36.4x1879x3.1x
Fri, 06 Jan 2023SEK 476.3bSEK 165.9bSEK 699.8m32.4x680.6x2.9x
Price to Earnings Ratio

680.6x


Total Market Cap: SEK 476.3bTotal Earnings: SEK 699.8mTotal Revenue: SEK 165.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -131.4x20242025
Current Industry PE
  • Investors are optimistic on the Swedish Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 160x which is higher than its 3-year average PE of -131x.
  • The industry is trading close to its 3-year average PS ratio of 2.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 73% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market0.44%
Healthcare0.53%
Life Sciences1.84%
Biotech0.86%
Medical Equipment0.34%
Healthcare Services0.32%
Pharma0.25%
Healthtech-0.25%
Industry PE
  • Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 123x.
    • Analysts are expecting annual earnings growth of 17.6%, which is lower than the prior year's growth of 46.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 39% over the next 5 years.
  • However this is lower than its past earnings growth rate of 97% per year.
  • In contrast, the Healthtech industry is expected to see its earnings grow by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GETI B GetingeSEK 217.602.1%
+SEK 1.2b		19.9%PE28.9x
SOBI Swedish Orphan BiovitrumSEK 333.400.7%
+SEK 758.2m		5.0%PE8839.1x
CAMX CamurusSEK 621.502.1%
+SEK 745.5m		9.9%PE47.4x
VIMIAN Vimian GroupSEK 30.643.7%
+SEK 581.5m		-23.0%PE47.6x
BIOG B BioGaiaSEK 105.304.2%
+SEK 424.9m		-5.9%PE33.7x

Latest News

BIOA B
SEK 313.40
BioArctic
7D
-1.4%
1Y
57.1%

BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks

Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.
VIMIAN
SEK 30.64
Vimian Group
7D
3.7%
1Y
-23.0%
BONEX
SEK 189.40
Bonesupport Holding
7D
2.7%
1Y
-51.0%

BONEX: De Novo Pathway Shift Will Support Strong Future Market Position

Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.
SANION
SEK 21.05
Saniona
7D
-2.1%
1Y
161.8%

There's No Escaping Saniona AB (publ)'s (STO:SANION) Muted Revenues Despite A 35% Share Price Rise

Dec 23
There's No Escaping Saniona AB (publ)'s (STO:SANION) Muted Revenues Despite A 35% Share Price Rise
STIL
SEK 198.00
Stille
7D
-2.9%
1Y
-4.8%

Returns At Stille (STO:STIL) Are On The Way Up

Dec 23
Returns At Stille (STO:STIL) Are On The Way Up
CAMX
SEK 621.50
Camurus
7D
2.1%
1Y
9.9%

CAMX: Positive Obesity Data Will Drive Future Upside Potential

Narrative Update on Camurus Analysts have modestly raised their price target on Camurus to reflect a fair value of approximately SEK 794 per share, citing sustained strong revenue growth expectations and robust long term profit margins as key drivers of the upward revision. What's in the News Reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide, showing dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with similar or better efficacy in a shorter treatment period (Key Developments).
SECT B
SEK 250.00
Sectra
7D
-1.2%
1Y
-9.6%

SECT B: Cloud Expansion Will Support Earnings Multiples Amid Balanced Risk

Analysts have raised their price target on Sectra from SEK 207.5 to SEK 245.0, citing slightly stronger long term revenue growth assumptions and a higher expected future earnings multiple, partly offset by a marginally lower profit margin outlook. What's in the News Sectra will provide a unified Sectra One Cloud enterprise imaging solution for four NHS trusts in Lancashire and South Cumbria, consolidating radiology and breast imaging across 15 hospitals to strengthen cybersecurity and collaboration (Client Announcements).
SUBGEN
SEK 0.94
Subgen AI
7D
-49.9%
1Y
n/a
GETI B
SEK 217.60
Getinge
7D
2.1%
1Y
19.9%
CURAS
DKK 12.15
Curasight
7D
-8.0%
1Y
41.9%
EKTA B
SEK 57.05
Elekta
7D
1.7%
1Y
-6.7%
SOBI
SEK 333.40
Swedish Orphan Biovitrum
7D
0.7%
1Y
5.0%

SOBI: Rare Disease Pipeline Progress Will Drive Future Share Price Upside

Analysts have raised their price target on Swedish Orphan Biovitrum from SEK 360 to SEK 367, reflecting slightly improved fair value assumptions and confidence in the company’s future earnings backed by recent positive research commentary. Analyst Commentary Recent upgrades reflect a growing conviction that Swedish Orphan Biovitrum can deliver attractive risk adjusted returns at current levels, with the new SEK 370 price target signaling modest upside from the revised fair value range.
AMBEA
SEK 140.80
Ambea
7D
-0.4%
1Y
45.8%

Why Ambea AB (publ) (STO:AMBEA) Could Be Worth Watching

Dec 15
Why Ambea AB (publ) (STO:AMBEA) Could Be Worth Watching
MCAP
SEK 550.00
MedCap
7D
-1.1%
1Y
-8.5%
BIOG B
SEK 105.30
BioGaia
7D
4.2%
1Y
-5.9%
VICO
SEK 11.52
Vicore Pharma Holding
7D
9.7%
1Y
36.3%